1,878 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 93.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 141 shares of the pharmaceutical company’s stock after selling 1,878 shares during the period. Clal Insurance Enterprises Holdings Ltd’s holdings in Vertex Pharmaceuticals were worth $74,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. MADDEN SECURITIES Corp bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth about $26,000. Meeder Asset Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $26,000. Community Financial Services Group LLC acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at about $26,000. Elevation Wealth Partners LLC lifted its holdings in shares of Vertex Pharmaceuticals by 103.7% in the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 28 shares in the last quarter. Finally, Pingora Partners LLC acquired a new position in Vertex Pharmaceuticals during the 2nd quarter valued at about $32,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Charles Wagner, Jr. sold 15,286 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $547.87, for a total value of $8,374,740.82. Following the completion of the transaction, the executive vice president directly owned 31,764 shares in the company, valued at approximately $17,402,542.68. The trade was a 32.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 271 shares of the business’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $547.86, for a total value of $148,470.06. Following the sale, the director owned 4,653 shares in the company, valued at approximately $2,549,192.58. The trade was a 5.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 16,557 shares of company stock valued at $9,071,071 over the last three months. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

VRTX has been the subject of a number of research analyst reports. Wells Fargo & Company increased their price target on Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. UBS Group boosted their price objective on Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a “buy” rating in a research report on Tuesday, November 3rd. Morgan Stanley reduced their price objective on Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating for the company in a research note on Tuesday, November 3rd. Evercore raised their target price on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research report on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. lifted their target price on Vertex Pharmaceuticals from $560.00 to $570.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $596.44.

Get Our Latest Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Stock Down 1.1%

VRTX opened at $514.75 on Friday. The company has a 50 day moving average of $522.72 and a 200 day moving average of $485.26. The company has a market cap of $130.51 billion, a PE ratio of 31.62, a price-to-earnings-growth ratio of 2.85 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 12 month low of $412.27 and a 12 month high of $568.67. The company has a current ratio of 2.34, a quick ratio of 1.89 and a debt-to-equity ratio of 0.17.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the prior year, the firm posted $4.80 earnings per share. The firm’s quarterly revenue was up 11.8% on a year-over-year basis. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current year.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Further Reading

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.